BPC-157 Contraindicated in Active Cancer BPC-157 promotes angiogenesis (new blood vessel formation), which means patients with active cancer should not use it
A new Cleveland Clinic study found those taking GLP-1s were less likely to develop stage IV disease in several cancer types, when compared to patients taking another diabetes medication, DPP-4 inhibitors
Retatrutide (LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly that activates three key metabolic pathways simultaneously
GLP-1 receptor agonists such as semaglutide (marketed under brand names Ozempic, Wegovy, and Rybelsus) and the dual GIP/GLP-1 agonist tirzepatide (marketed under brand names Mounjaro and Zepbound) are FDA-approved prescription medications for specific uses in type 2 diabetes management and, in some cases, chronic weight management
Lipotropics are nutrients, vitamins, and other ingredients that may help boost your metabolism and slow down or remove fat deposits in your liver
Hoppe JB, Coradini K, Frozza RL, Oliveira CM, Meneghetti AB, Bernardi A, et al